Schizophrenia<unk>  is an effective antipsychotic for people with schizophrenia. There is low-quality evidence that<unk>  increases the chance of being improved when compared to placebo when people are followed up for 19 weeks. There is low-quality evidence that<unk>  reduces the risk of relapse when compared with placebo when people are followed for 5 months. As of 2014 there was no good evidence for a difference between<unk>  and placebo with respect to the risk of experiencing intensified symptoms over a 16-week period nor in reducing significant agitation or distress. There is no good evidence that<unk>  is more effective for schizophrenia than lower-potency antipsychotics like chlorpromazine, chlorprothixene, thioridazine and levomepromazine, but<unk>  appears to cause more adverse effects than these drugs. Other It appears to be effective for people with generalized anxiety disorder but the benefitrisk ratio was unclear as of 2005. It has been experimentally used as a drug to kill eukaryotic pathogens in humans.
Trifluoperazine
Levocetirizine
Iloperidone
Loperamide
Ethacizine
Benadryl
Sucralfate
Transfluthrin